Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial

British Journal of Anaesthesia

Volumn 117, Issue 6, 2016, Pages 775-782

  Nascimento, B ^a   Callum, J ^a   Tien, H ^a   Peng, H ^a   Rizoli, S ^a   Karanicolas, P ^a   Alam, A ^a   Xiong, W ^a   Selby, R ^a   Garzon, A M ^a   Colavecchia, C ^a   Howald, R ^a   Nathens, A ^a   Beckett, A ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Fibrinogen concentrate; haemorrhage management; plasma fibrinogen; trauma; trauma coagulopathy

Indexed keywords

FIBRINOGEN; FIBRINOGEN CONCENTRATE; PLACEBO;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALL CAUSE MORTALITY; ARTERIAL PRESSURE; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEASIBILITY STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HOSPITALIZATION; HUMAN; INFECTION; INJURY; LUNG EMBOLISM; MALE; MIDDLE AGED; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SEPSIS; THROMBOEMBOLISM; AGED; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; RESUSCITATION; TREATMENT OUTCOME; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 85016485777     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aew343     Document Type: Article

References (43)

1. Sauaia, A, Moore, FA, Moore, EE, et al. Epidemiology of trauma deaths. J Trauma 38 (1995), 185–193.
2. Acosta, JA, Yang, JC, Winchell, RJ, et al. Lethal injuries and time to death in a level I trauma center. J Am Coll Surg 186 (1998), 528–533.
3. MacLeod, JBA, Lynn, M, McKenney, MG, Cohn, SM, Murtha, M., Early coagulopathy predicts mortality in trauma. J Trauma 55 (2003), 39–44.
4. Tisherman, SA, Schmicker, RH, Brasel, KJ, et al. Detailed description of all deaths in both the shock and traumatic brain injury hypertonic saline trials of the resuscitation outcomes consortium. Ann Surg 261 (2015), 586–590.
5. Fries, D, Martini, WZ., Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth 105 (2010), 116–121.
6. Levy, JH, Szlam, F, Tanaka, KA, Sniecienski, RM., Fibrinogen and hemostasis. Anesth Analg 114 (2012), 261–274.
7. Hess, JR, Brohi, K, Dutton, RP, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 65 (2008), 748–754.
8. Hiippala, ST, Myllyla, GJ, Vahtera, EM, Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 8 (1995), 359–360.
9. Rourke, C, Curry, N, Khan, S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 10 (2012), 1342–1351.
10. Stinger, HK, Spinella, PC, Perkins, JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an Army Combat Support Hospital. J Trauma 64 (2008), S79–S85.
11. Nienaber, U, Innerhofer, P, Westermann, I, et al. The impact of fresh frozen plasma vs coagulation factor concentrates on morbidity and mortality in trauma-associated haemorrhage and massive transfusion. Injury 42 (2011), 697–701.
12. ®)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care, 14, 2010, R55.
13. Schöchl, H, Nienaber, U, Maegele, M, et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care, 15, 2011, R83.
14. Weiss, G, Lison, S, Glaser, M, et al. Observational study of fibrinogen concentrate in massive hemorrhage. Blood Coagul Fibrinolysis 22 (2011), 727–734.
15. Wafaisade, A, Lefering, R, Maegele, M, et al. Administration of fibrinogen concentrate in exsanguinating trauma pa1tients is associated with improved survival at 6 hours but not at discharge. J Trauma Acute Care Surg 74 (2013), 387–395.
16. Schlimp, CJ, Voelckel, W, Inaba, K, Maegele, M, Schöchl, H., Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/− fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma: a retrospective study. Scand J Trauma Resusc Emerg Med, 21, 2013, 74.
17. Spahn, DR, Bouillon, B, Cerny, V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care, 17, 2013, R76.
18. Nascimento, B, Rizoli, S, Rubenfeld, G, et al. Cryoprecipitate transfusion: assessing appropriateness and dosing in trauma. Transfus Med 21 (2011), 394–401.
19. Holcomb, JB, Fox, EE, Zhang, X, et al. Cryoprecipitate use in the PROMMTT study. J Trauma Acute Care Surg 75 (2013), S31–S39.
20. Curry, N, Rourke, C, Davenport, R, et al. Early cryoprecipitate for major haemorrhage in trauma: a randomised controlled feasibility trial. Br J Anaesth 115 (2015), 76–83.
21. Callum, JL, Karkouti, K, Lin, Y., Cryoprecipitate: the current state of knowledge. Transfus Med Rev 23 (2009 Jul), 177–188.
22. Costa-Filho, R, Hochleitner, G, Wendt, M, Teruya, A, Spahn, DR., Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost 22 (2016), 109–114.
23. Kozek-Langenecker, S, Sørensen, B, Hess, JR, Spahn, DR., Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care, 15, 2011, R239.
24. Aubron, C, Reade, MC, Fraser, JF, Cooper, DJ., Efficacy and safety of fibrinogen concentrate in trauma patients—a systematic review. J Crit Care 29 (2014), 471.e11–471.e17.
25. Nascimento, B, Rizoli, S, Rubenfeld, G, et al. Design and preliminary results of a pilot randomized controlled trial on a 1:1:1 transfusion strategy: the trauma formula-driven versus laboratory-guided study. J Trauma 71 (2011), S418–S426.
26. Tri-Council Policy Working Party on Ethics. Draft 2nd Edition of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2010 Article 3.8 http://www.pre.ethics.gc.ca/pdf/eng/tcps2/TCPS_2_FINAL_Web.pdf.
27. Warmuth, M, Mad, P, Wild, C., Systematic review of the efficacy and safety of fibrinogen concentrate substitution in adults. Acta Anaesthesiol Scand 56 (2011), 539–548.
28. Wikkelsø A, Lunde, J, Johansen, M, et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev, 8, 2013, CD008864.
29. Solomon, C, Pichlmaier, U, Schoechl, H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 104 (2010), 555–562.
30. Rahe-Meyer, N, Solomon, C, Hanke, A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery. Anesthesiology 118 (2013), 40–50.
31. Rahe-Meyer, N, Hanke, A, Schmidt, DS, Hagl, C, Pichlmaier, M., Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: Results from a randomized, placebo-controlled trial. J Thorac Cardiovasc Surg 145 (2013), S178–S185.
32. Solomon, C, Hagl, C, Rahe-Meyer, N., Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. Br J Anaesth 110 (2013), 947–956.
33. Danés, AF, Cuenca, LG, Bueno, SR, Mendarte Barrenechea, L, Ronsano, JBM., Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 94 (2008), 221–226.
34. Callum, JL, Nascimento, B, Alam, A., Massive haemorrhage protocol: what's the best protocol?. ISBT Science Series 11 (2016), 297–306.
35. Gollop, ND, Chilcott, J, Benton, A, et al. National audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia. Transfus Med 22 (2012), 350–355.
36. Innerhofer, P, Westermann, I, Tauber, H, et al. The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury 44 (2013), 209–216.
37. Karlsson, M, Ternström, L, Hyllner, M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost 102 (2009), 137–144.
38. Fenger-Eriksen, C, Jensen, TM, Kristensen, BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 7 (2009), 795–802.
39. Martini, WZ, Dubick, MA., Fibrinogen concentrate administration inhibits endogenous fibrinogen synthesis in pigs after traumatic hemorrhage. J Trauma Acute Care Surg 79 (2015), 540–547 discussion 547–8.
40. Lin, DM, Murphy, LS, Tran, M-H., Use of prothrombin complex concentrates and fibrinogen concentrates in the perioperative setting: a systematic review. Transfus Med Rev 27 (2013), 91–104.
41. Solomon, C, Groner, A, Ye, J, Pendrak, I., Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data. Thromb Haemost 113 (2015), 759–771.
42. Hildebrand, F, Pape, HC, Horst, K, et al. Impact of age on the clinical outcomes of major trauma. Eur J Trauma Emerg Surg 42 (2016), 317–332.
43. Fergusson, D., Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. Br Med J 325 (2002), 652–654.